The first FDA-approved drug to block immune checkpoints was the human anti-CTLA-4 monoclonal antibody, ipilimumab [59], used for the treatment of melanoma (CTLA-4—a co-inhibitor that inhibits T cell activation). The gene discussed is CTLA4; the disease is melanoma.